CASTLE BIOSCIENCES, INC. (CSTL) Operating Margin
- Operating margin · 12 months: Value -8.99%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -8.99% | Operating income / revenue. Period ending 2026-06-30. $-32.11M ÷ $357.28M × 100 ≈ -8.99% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -32.11M USD | Operating Income (Loss) |
| Revenue | 357.28M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 55.45M USD | Research and Development Expense |
| Selling, general and administration | 243.66M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-32.11M | $357.28M | (m) | $55.45M | $243.66M | -8.99% |
| 2026-03-31 | $-33.29M | $339.92M | (m) | $53.69M | $235.60M | -9.79% |
| 2025-12-31 | $-42.81M | $344.23M | (m) | $51.85M | $229.32M | -12.44% |
| 2025-09-30 | $-34.93M | $343.53M | (m) | $50.11M | $222.56M | -10.17% |
| 2025-06-30 | $-23.05M | $346.27M | (m) | $49.47M | $217.15M | -6.66% |
| 2025-03-31 | $-13.79M | $347.08M | (m) | $50.82M | $210.17M | -3.97% |
| 2024-12-31 | $8.67M | $332.07M | (m) | $52.04M | $200.05M | 2.61% |
| 2024-09-30 | $-1.04M | $311.88M | (m) | $53.26M | $194.17M | -0.33% |
| 2024-06-30 | $-15.76M | $287.59M | (m) | $53.86M | $188.29M | -5.48% |
| 2024-03-31 | $-41.93M | $250.72M | (m) | $53.03M | $181.88M | -16.72% |
| 2023-12-31 | $-67.98M | $219.79M | (m) | $53.62M | $180.15M | -30.93% |
| 2023-09-30 | $-85.15M | $192.01M | (m) | $51.93M | $174.49M | -44.35% |
| 2023-06-30 | $-97.05M | $167.52M | (m) | $49.92M | $166.50M | -57.93% |
| 2023-03-31 | $-79.86M | $152.22M | (m) | $48.53M | $159.31M | -52.46% |
| 2022-12-31 | $-72.86M | $137.04M | (m) | $44.90M | $143.00M | -53.16% |
| 2022-09-30 | $-65.19M | $123.74M | (m) | $43.04M | $129.74M | -52.69% |
| 2022-06-30 | $-55.47M | $110.20M | (m) | $39.63M | $115.71M | -50.34% |
| 2022-03-31 | $-60.31M | $98.12M | (m) | $34.50M | $99.03M | -61.46% |
| 2021-12-31 | $-40.08M | $94.08M | $15.82M | $29.65M | $86.74M | -42.60% |
| 2021-09-30 | $-27.94M | $86.34M | (m) | $24.78M | $76.54M | -32.36% |
| 2021-06-30 | $-20.03M | $78.09M | (m) | $20.34M | $65.64M | -25.65% |
| 2021-03-31 | $-11.86M | $68.04M | $10.32M | $16.25M | $55.22M | -17.43% |
| 2020-12-31 | $-6.54M | $62.65M | $9.69M | $13.26M | $48.13M | -10.44% |
| 2020-09-30 | $-897.00K | $62.98M | $9.02M | $11.83M | $43.02M | -1.42% |
| 2020-06-30 | $7.43M | $62.54M | $8.26M | $10.29M | $38.44M | 11.88% |
| 2020-03-31 | $8.69M | $60.57M | $8.10M | $8.90M | $34.87M | 14.34% |
| 2019-12-31 | $7.33M | $51.87M | $7.31M | $7.38M | $29.84M | 14.13% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $27.84M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-3.84M | $22.79M | $5.30M | $4.85M | $16.47M | -16.83% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |